Big firms are planning to cut the cash they put into employees' pensions this year. Investors are hoping to get their hands on the money instead—USAT.» Read More
Becton, Dickinson& Co. rose$. 32 or. 3 percent, to $118.22. Covidien rose$. 72 or. 8 percent, to $88.44. PerkinElmer fell$. 26 or. 6 percent, to $45.60.
Becton, Dickinson& Co. fell$. 02 or percent, to $117.88. Covidien rose$. 36 or. 4 percent, to $88.08. PerkinElmer fell$. 33 or. 7 percent, to $45.53.
Becton, Dickinson& Co. rose$. 63 or. 5 percent, to $117.90. Covidien rose$. 61 or. 7 percent, to $87.72. PerkinElmer rose$. 53 or 1.2 percent, to $45.86.
Becton, Dickinson& Co. rose$. 63 or. 5 percent, to $117.90. Covidien plc rose$. 52 or. 6 percent, to $87.63. PerkinElmer rose$. 18 or. 4 percent, to $45.51.
Check out which companies are making headlines after the bell Monday:
Jim Cramer thinks this company could unlock significant value with the simple stroke of a pen.
Check out which companies are making headlines after the bell Thursday:
Shares of PerkinElmer soared to a new annual high, a day after the health and industrial sciences company reported third-quarter results that topped Wall Street expectations. PerkinElmer Inc. said Thursday it now expects adjusted 2012 earnings of $2.05 to $2.07 per share. THE BIG PICTURE: PerkinElmer runs human and environmental health businesses.
Analyst Sung Ji Nam said that for now, the major sources of growth for companies including Illumina Inc. and Life Technologies Corp. will be sales of new, more advanced gene-sequencing products and disposable items used in testing, and their biggest clients will remain academic and clinical customers.
*JP Morgan starts PerkinElmer with overweight- Streetinsider.com. Reuters Station users, click. 1568. Reuters Station users, click. 4899.
NEW YORK-- Analysts for Cowen and Co. started coverage of a group of companies that make tests used to diagnose infectious diseases, assigning top ratings to companies including Cepheid, Hologic Inc., and Meridian Bioscience Inc..
Take a look at some of Tuesday’s morning movers:
Cramer makes the call on viewers' favorite stocks.
What follows is a look at stocks in the S&P 1,500 displaying unusual volume in Tuesday's trading session.
The Lightning Round is extended in this CNBC.com exclusive feature.
Cramer thinks this is it. Check out his interview with this company's CEO.
Japan's nuclear crisis could give added business to a company already doing "incredibly well."
Plus, get calls on agriculture, gold, retail and more.
Plus, are Apple’s earnings estimates too low?
And Cramer likes it. Check out his interview with the CEO.